|
1
|
Miao S, Qiu T, Zhao Y, Wang H, Sun X, Wang
Y, Xuan Y, Qin Y and Jiao W: Overexpression of S100A13 protein is
associated with tumor angiogenesis and poor survival in patients
with early-stage non-small cell lung cancer. Thorac Cancer.
9:1136–1144. 2018. View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar
|
|
3
|
Morgant MC, Pages PB, Orsini B, Falcoz PE,
Thomas PA, Barthes Fle P, Dahan M and Bernard A; Epithor project
(French Society of Thoracic and Cardiovascular Surgery), : Time
trends in surgery for lung cancer in France from 2005 to 2012: A
nationwide study. Eur Respir J. 46:1131–1139. 2015. View Article : Google Scholar
|
|
4
|
Wu AJ, Garay E, Foster A, Hsu M, Zhang Z,
Chaft JE, Huang J, Rosenzweig KE and Rimner A: Definitive
radiotherapy for local recurrence of NSCLC after surgery. Clin Lung
Cancer. 18:e161–e168. 2017. View Article : Google Scholar
|
|
5
|
Hattori A, Matsunaga T, Takamochi K, Oh S
and Suzuki K: Locoregional recurrence after segmentectomy for
clinical-T1aN0M0 radiologically solid non-small-cell lung
carcinoma. Eur J Cardiothorac Surg. 51:518–525. 2017.
|
|
6
|
Mghwary AE, Gedawy EM, Kamal AM and
Abuel-Maaty SM: Novel thienopyrimidine derivatives as dual EGFR and
VEGFR-2 inhibitors: Design, synthesis, anticancer activity and
effect on cell cycle profile. J Enzyme Inhib Med Chem. 34:838–852.
2019. View Article : Google Scholar
|
|
7
|
Reckamp KL, Frankel PH, Ruel N, Mack PC,
Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, et
al: Phase II trial of cabozantinib plus erlotinib in patients with
advanced epidermal growth factor receptor (EGFR)-mutant non-small
cell lung cancer with progressive disease on epidermal growth
factor receptor tyrosine kinase inhibitor therapy: A California
Cancer Consortium phase II trial (NCI 9303). Front Oncol.
9:1322019. View Article : Google Scholar
|
|
8
|
Yang KM, Shin IC, Park JW, Kim KS, Kim DK,
Park K and Kim K: Nanoparticulation improves bioavailability of
erlotinib. Drug Dev Ind Pharm. 43:1557–1565. 2017. View Article : Google Scholar
|
|
9
|
Cardona AF, Arrieta O, Zapata MI, Rojas L,
Wills B, Reguart N, Karachaliou N, Carranza H, Vargas C, Otero J,
et al: Acquired resistance to erlotinib in EGFR mutation-positive
lung adenocarcinoma among hispanics (CLICaP). Target Oncol.
12:513–523. 2017. View Article : Google Scholar
|
|
10
|
Hu H, Miao XK, Li JY, Zhang XW, Xu JJ,
Zhang JY, Zhou TX, Hu MN, Yang WL and Mou LY: YC-1 potentiates the
antitumor activity of gefitinib by inhibiting HIF-1α and promoting
the endocytic trafficking and degradation of EGFR in
gefitinib-resistant non-small-cell lung cancer cells. Eur J
Pharmacol. 874:1729612020. View Article : Google Scholar
|
|
11
|
Gandhi J, Zhang J, Xie Y, Soh J,
Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW,
et al: Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung
cancer cell lines. PLoS One. 4:e45762009. View Article : Google Scholar
|
|
12
|
Li Y, Fan S, Koo J, Yue P, Chen ZG,
Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: Elevated
expression of eukaryotic translation initiation factor 4E is
associated with proliferation, invasion and acquired resistance to
erlotinib in lung cancer. Cancer Biol Ther. 13:272–280. 2012.
View Article : Google Scholar
|
|
13
|
Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK,
Sica GL, Ramalingam SS, Curran WJ, Khuri FR and Deng X: Niclosamide
overcomes acquired resistance to erlotinib through suppression of
STAT3 in non-small cell lung cancer. Mol Cancer Ther. 12:2200–2212.
2013. View Article : Google Scholar
|
|
14
|
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and
Settleman J: Drug resistance via feedback activation of Stat3 in
oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014.
View Article : Google Scholar
|
|
15
|
Lou W, Chen Y, Zhu KY, Deng H, Wu T and
Wang J: Polyphyllin I overcomes EMT-associated resistance to
erlotinib in lung cancer cells via IL-6/STAT3 pathway inhibition.
Biol Pharm Bull. 40:1306–1313. 2017. View Article : Google Scholar
|
|
16
|
Chen G, Bao Y, Weng Q, Zhao Y, Lu X, Fu L,
Chen L, Liu Z, Zhang X and Liang G: Compound 15c, a novel dual
inhibitor of EGFRL858R/T790M and FGFR1, efficiently
overcomes epidermal growth factor receptor-tyrosine kinase
inhibitor resistance of non-small-cell lung cancers. Front
Pharmacol. 10:15332020. View Article : Google Scholar
|
|
17
|
Hsu YL, Kuo PL, Tzeng TF, Sung SC, Yen MH,
Lin LT and Lin CC: Huang-lian-jie-du-tang, a traditional Chinese
medicine prescription, induces cell-cycle arrest and apoptosis in
human liver cancer cells in vitro and in vivo. J Gastroenterol
Hepatol. 23:e290–e299. 2008. View Article : Google Scholar
|
|
18
|
He MY, Deng YX, Shi QZ, Zhang XJ and Lv Y:
Comparative pharmacokinetic investigation on baicalin and
wogonoside in type 2 diabetic and normal rats after oral
administration of traditional Chinese medicine Huanglian Jiedu
decoction. J Ethnopharmacol. 155:334–342. 2014. View Article : Google Scholar
|
|
19
|
Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X,
Wu R, Lv Y and Dong J: Baicalein and baicalin promote antitumor
immunity by suppressing PD-L1 expression in hepatocellular
carcinoma cells. Int Immunopharmacol. 75:1058242019. View Article : Google Scholar
|
|
20
|
Wang HY, Yu HZ, Huang SM and Zheng YL:
P53, Bcl-2 and cox-2 are involved in berberine
hydrochloride-induced apoptosis of HeLa229 cells. Mol Med Rep.
14:3855–3861. 2016. View Article : Google Scholar
|
|
21
|
Zhu M, Ying J, Lin C, Wang Y, Huang K,
Zhou Y and Teng H: Baicalin induces apoptotic death of human
chondrosarcoma cells through mitochondrial dysfunction and
downregulation of the PI3K/Akt/mTOR pathway. Planta Med.
85:360–369. 2019. View Article : Google Scholar
|
|
22
|
Wu X, Liu P, Zhang H, Li Y, Salmani JM,
Wang F, Yang K, Fu R, Chen Z and Chen B: Wogonin as a targeted
therapeutic agent for EBV (+) lymphoma cells involved in
LMP1/NF-κB/miR-155/PU.1 pathway. BMC Cancer. 17:1472017. View Article : Google Scholar
|
|
23
|
Shan F, Shao Z, Jiang S and Chen Z:
Erlotinib induces the human non-small-cell lung cancer cells
apoptosis via activating ROS-dependent JNK pathways. Cancer Med.
5:3166–3175. 2016. View
Article : Google Scholar
|
|
24
|
Ji XL and He M: Sodium cantharidate
targets STAT3 and abrogates EGFR inhibitor resistance in
osteosarcoma. Aging (Albany NY). 11:5848–5863. 2019. View Article : Google Scholar
|
|
25
|
Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY
and Chen YB: JAK2 inhibitor TG101348 overcomes erlotinib-resistance
in non-small cell lung carcinoma cells with mutated EGF receptor.
Oncotarget. 6:14329–14343. 2015. View Article : Google Scholar
|
|
26
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar
|
|
27
|
Citri A and Yarden Y: EGF-ERBB signalling:
Towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar
|
|
28
|
Wang Z: ErbB receptors and cancer. Methods
Mol Biol. 1652:3–35. 2017. View Article : Google Scholar
|
|
29
|
Carcereny E, Moran T, Capdevila L, Cros S,
Vilà L, de Los Llanos Gil M, Remón J and Rosell R: The epidermal
growth factor receptor (EGRF) in lung cancer. Transl Respir Med.
3:12015. View Article : Google Scholar
|
|
30
|
Marmor MD, Skaria KB and Yarden Y: Signal
transduction and oncogenesis by ErbB/HER receptors. Int J Radiat
Oncol Biol Phys. 58:903–913. 2004. View Article : Google Scholar
|
|
31
|
Prickett TD, Agrawal NS, Wei X, Yates KE,
Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA and Samuels
Y: Analysis of the tyrosine kinome in melanoma reveals recurrent
mutations in ERBB4. Nat Genet. 41:1127–1132. 2009. View Article : Google Scholar
|
|
32
|
Skoulidis F and Papadimitrakopoulou VA:
Targeting the gatekeeper: Osimertinib in EGFR T790M
mutation-positive non-small cell lung cancer. Clin Cancer Res.
23:618–622. 2017. View Article : Google Scholar
|
|
33
|
Wu P, Nielsen TE and Clausen MH:
FDA-approved small-molecule kinase inhibitors. Trends Pharmacol
Sci. 36:422–439. 2015. View Article : Google Scholar
|
|
34
|
Agustoni F, Suda K, Yu H, Ren S, Rivard
CJ, Ellison K, Caldwell C Jr, Rozeboom L, Brovsky K and Hirsch FR:
EGFR-directed monoclonal antibodies in combination with
chemotherapy for treatment of non-small-cell lung cancer: An
updated review of clinical trials and new perspectives in
biomarkers analysis. Cancer Treat Rev. 72:15–27. 2019. View Article : Google Scholar
|
|
35
|
Russo A, Franchina T, Ricciardi GR, Picone
A, Ferraro G, Zanghì M, Toscano G, Giordano A and Adamo V: A decade
of EGFR inhibition in EGFR-mutated non small cell lung cancer
(NSCLC): Old successes and future perspectives. Oncotarget.
6:26814–26825. 2015. View Article : Google Scholar
|
|
36
|
Thatcher N, Chang A, Parikh P, Rodrigues
Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar
|
|
37
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar
|
|
38
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar
|
|
39
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar
|
|
40
|
Li YL, Pan YN, Wu WJ, Mao SY, Sun J, Zhao
YM, Dong JY, Zhang DY, Pan JP, Zhang C and Lin NM: Evodiamine
induces apoptosis and enhances apoptotic effects of erlotinib in
wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition. Med
Oncol. 33:162016. View Article : Google Scholar
|
|
41
|
Yang K, Chen Y, Zhou J, Ma L, Shan Y,
Cheng X, Wang Y, Zhang Z, Ji X, Chen L, et al: Ursolic acid
promotes apoptosis and mediates transcriptional suppression of
CT45A2 gene expression in non-small-cell lung carcinoma harbouring
EGFR T790M mutations. Br J Pharmacol. 176:4609–4624. 2019.
View Article : Google Scholar
|
|
42
|
Ma Z, Otsuyama K, Liu S, Abroun S,
Ishikawa H, Tsuyama N, Obata M, Li FJ, Zheng X, Maki Y, et al:
Baicalein, a component of Scutellaria radix from
Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of
proliferation and induction of apoptosis in human myeloma cells.
Blood. 105:3312–3318. 2005. View Article : Google Scholar
|
|
43
|
Lee WR, Shen SC, Lin HY, Hou WC, Yang LL
and Chen YC: Wogonin and fisetin induce apoptosis in human
promyeloleukemic cells, accompanied by a decrease of reactive
oxygen species, and activation of caspase 3 and Ca(2+)-dependent
endonuclease. Biochem Pharmacol. 63:225–236. 2002. View Article : Google Scholar
|
|
44
|
Bonham M, Posakony J, Coleman I,
Montgomery B, Simon J and Nelson PS: Characterization of chemical
constituents in Scutellaria baicalensis with antiandrogenic and
growth-inhibitory activities toward prostate carcinoma. Clin Cancer
Res. 11:3905–3914. 2005. View Article : Google Scholar
|
|
45
|
Himeji M, Ohtsuki T, Fukazawa H, Tanaka M,
Yazaki S, Ui S, Nishio K, Yamamoto H, Tasaka K and Mimura A:
Difference of growth-inhibitory effect of Scutellaria
baicalensis-producing flavonoid wogonin among human cancer cells
and normal diploid cell. Cancer Lett. 245:269–274. 2007. View Article : Google Scholar
|
|
46
|
Bosse K, Haneder S, Arlt C, Ihling CH,
Seufferlein T and Sinz A: Mass spectrometry-based secretome
analysis of non-small cell lung cancer cell lines. Proteomics.
16:2801–2814. 2016. View Article : Google Scholar
|
|
47
|
Serizawa M, Murakami H, Watanabe M,
Takahashi T, Yamamoto N and Koh Y: Peroxisome
proliferator-activated receptor ү agonist efatutazone impairs
transforming growth factor β2-induced motility of epidermal growth
factor receptor tyrosine kinase inhibitor-resistant lung cancer
cells. Cancer Sci. 105:683–689. 2014. View Article : Google Scholar
|
|
48
|
Song J, Zhong R, Huang H, Zhang Z, Ding D,
Yan H, Sun E and Jia X: Combined treatment with Epimedium koreanum
Nakai extract and gefitinib overcomes drug resistance caused by
T790M mutation in non-small cell lung cancer cells. Nutr Cancer.
66:682–689. 2014. View Article : Google Scholar
|
|
49
|
Chen Y, Zeng Z and Lu Y: Is mIndy a
mediator of energy metabolism reprogramming in hepatocellular
carcinoma induced by interleukin-6/signal transducer and activator
of transcription 3 signaling? Hepatology. 67:451–452. 2018.
View Article : Google Scholar
|
|
50
|
Liu X, Wei W, Li X, Shen P, Ju D, Wang Z,
Zhang R, Yang F, Chen C, Cao K, et al: BMI1 and MEL18 promote
colitis-associated cancer in mice via REG3B and STAT3.
Gastroenterology. 153:1607–1620. 2017. View Article : Google Scholar
|
|
51
|
Atsaves V, Tsesmetzis N, Chioureas D, Kis
L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ,
Young KH and Rassidakis GZ: PD-L1 is commonly expressed and
transcriptionally regulated by STAT3 and MYC in ALK-negative
anaplastic large-cell lymphoma. Leukemia. 31:1633–1637. 2017.
View Article : Google Scholar
|
|
52
|
Yamaguchi M, Suzuki R, Kwong YL, Kim WS,
Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K and
Oshimi K: Phase I study of dexamethasone, methotrexate, ifosfamide,
L-asparaginase, and etoposide (SMILE) chemotherapy for
advanced-stage, relapsed or refractory extranodal natural killer
(NK)/T-cell lymphoma and leukemia. Cancer Sci. 99:1016–1020. 2008.
View Article : Google Scholar
|
|
53
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar
|
|
54
|
Xiao Q, Zheng F, Wu J, Tang Q, Wang W and
Hann SS: Activation of ERK and mutual regulation of Stat3 and SP1
contribute to inhibition of PDK1 expression by atractylenolide-1 in
human lung cancer cells. Cell Physiol Biochem. 43:2353–2366. 2017.
View Article : Google Scholar
|
|
55
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar
|
|
56
|
Van Schaeybroeck S, Kalimutho M, Dunne PD,
Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S,
Blayney J, et al: ADAM17-dependent c-MET-STAT3 signaling mediates
resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell
Rep. 7:1940–1955. 2014. View Article : Google Scholar
|
|
57
|
Li G, Zhao L, Li W, Fan K, Qian W, Hou S,
Wang H, Dai J, Wei H and Guo Y: Feedback activation of STAT3
mediates trastuzumab resistance via upregulation of MUC1 and MUC4
expression. Oncotarget. 5:8317–8329. 2014. View Article : Google Scholar
|
|
58
|
Zhao C, Li H, Lin HJ, Yang S, Lin J and
Liang G: Feedback activation of STAT3 as a cancer drug-resistance
mechanism. Trends Pharmacol Sci. 37:47–61. 2016. View Article : Google Scholar
|
